
1. world j gastroenterol. 2008 jul 14;14(26):4120-6.

hepatic steatosis: benign disease silent killer.

el-zayadi ar.

steatosis common feature many liver diseases, namely non-alcoholic
steatohepatitis (nash) hepatitis c virus (hcv) infection, pathogenic 
mechanisms differ. insulin resistance (ir), key feature metabolic syndrome, 
is crucial nash development, associated many underlying genetically
determined acquired mitochondrial metabolic defects culminates to
inflammation progression fibrosis. may potential implications
for new drug therapy. hcv-related disease, steatosis impacts fibrosis
progression response treatment. steatosis hcv-related disease relates
to viral factors (hcv genotype 3), host factors (alcohol consumption,
overweight, hyperlipidemia, diabetes). among others, ir recognized factor.
hepatic steatosis reported associated disturbance signaling 
cascade interferon downregulation receptors. thus, hepatic
steatosis considered benign feature, rather silent killer.

doi: 10.3748/wjg.14.4120 
pmcid: pmc2725370
pmid: 18636654  [indexed medline]

